Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Small Cell Lung Carcinoma × amuvatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Waldenstrom Macroglobulinemia 1 Small Cell Lung Carcinoma 1 Sezary Syndrome 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasms 1 Mycosis Fungoides 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large-Cell, Immunoblastic 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Intraocular Lymphoma 1 Immunoblastic Lymphadenopathy 1 Hodgkin Disease 1 Burkitt Lymphoma 1

Interventions

Etoposide 136 Carboplatin 124 Cisplatin 93 Topotecan 66 durvalumab 46 Irinotecan 41 atezolizumab 40 pembrolizumab 32 Nivolumab 29 Radiotherapy 28 Paclitaxel 28 PM 01183 20 anlotinib 19 Drug Therapy 19 apatinib 18 Gemcitabine 18 Ipilimumab 17 Platinum 16 Docetaxel 15 olaparib 13 Radiosurgery 13 Bevacizumab 13 Pemetrexed 12 toripalimab 11 rovalpituzumab tesirine 10 amrubicin 10 Temozolomide 10 tremelimumab 9 tislelizumab 9 Magnetic Resonance Spectroscopy 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01357395 2024-08-02

ESCAPE

Astex Pharmaceuticals, Inc.

Phase 2 Completed

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡